Common misconceptions
Common mistake
Wrong: Pegvisomant works by suppressing GH secretion from the pituitary.
Right: Pegvisomant is a GH receptor antagonist that blocks GH action at peripheral tissues, reducing IGF-1 production without affecting GH secretion itself.
Pegvisomant is a GH receptor antagonist — it doesn't touch the pituitary at all. It blocks GH from binding its receptor in peripheral tissues (mainly the liver), so hepatic IGF-1 production drops. The key tell: GH levels actually rise or stay elevated on pegvisomant because there's no negative feedback suppression of pituitary secretion. If you monitor treatment response, you follow IGF-1, not GH, because GH itself will look normal-to-elevated while the patient is actually well-controlled.
Common mistake
Wrong: Somatostatin analogs like octreotide directly block the GH receptor to lower IGF-1.
Right: Octreotide binds somatostatin receptors on the pituitary tumor to suppress GH secretion, which secondarily reduces hepatic IGF-1 production.
Octreotide doesn't touch the GH receptor — it binds somatostatin receptors (SSTR2 and SSTR5) on the pituitary tumor cells, which suppresses GH secretion upstream. Lower GH means the liver produces less IGF-1 as a downstream consequence. This is an entirely different point of intervention from pegvisomant, which acts at the GH receptor itself in peripheral tissue. Think of octreotide as turning down the faucet (GH secretion) versus pegvisomant blocking the drain (GH action).
Common mistake
Wrong: Cabergoline is as effective as somatostatin analogs for most acromegaly patients and can be used as first-line monotherapy.
Right: Cabergoline (a dopamine agonist) has modest efficacy in acromegaly and is generally reserved for mild disease or used as adjunctive therapy; somatostatin analogs are the preferred medical agents.
Cabergoline works in acromegaly because GH-secreting tumors often co-express dopamine D2 receptors, and dopamine agonism paradoxically suppresses GH in these patients (opposite of its effect in normal people). However, this effect is modest — response rates are substantially lower than with somatostatin analogs. Cabergoline is generally reserved for patients with mild IGF-1 elevation, mixed GH/prolactin-secreting tumors, or as an add-on agent. Calling it equivalent first-line to octreotide would be wrong on USMLE Step 1.
Can you avoid these mistakes?
A patient with acromegaly is started on a drug and their follow-up labs show GH levels are actually higher than before treatment, yet IGF-1 has normalized. Which drug is this and why does this pattern occur?
You're given three acromegaly drugs: octreotide, pegvisomant, and cabergoline. Rank them from most to least efficacious for the average acromegaly patient, and justify the ranking by mechanism.
A GH-secreting pituitary tumor is resected but post-op IGF-1 remains elevated. The endocrinologist prescribes octreotide. At what step in the GH/IGF-1 axis does octreotide intervene, and how does this differ from where pegvisomant acts?
A patient has a mixed GH- and prolactin-secreting pituitary tumor with only mildly elevated IGF-1. Which pharmacologic agent might be especially attractive to try first, and why does it work in this setting despite its modest overall efficacy in acromegaly?